tetano
Editor, Senior Moderator
Cytokine
. 2021 Jul 3;146:155634.
doi: 10.1016/j.cyto.2021.155634. Online ahead of print.
Clinical applications of thrombopoietin silencing: A possible therapeutic role in COVID-19?
Vincent J Alentado[SUP] 1 [/SUP], Alison R Moliterno[SUP] 2 [/SUP], Edward F Srour[SUP] 3 [/SUP], Melissa A Kacena[SUP] 4 [/SUP]
Affiliations
Abstract
Thrombopoietin (TPO) is most recognized for its function as the primary regulator of megakaryocyte (MK) expansion and differentiation. MKs, in turn, are best known for their role in platelet production. Research indicates that MKs and platelets play an extensive role in the pathologic thrombosis at sites of high inflammation. TPO, therefore, is a key mediator of thromboinflammation. Silencing of TPO has been shown to decrease platelets levels and rates of pathologic thrombosis in patients with various inflammatory disorders (Barrett et al, 2020; Bunting et al, 1997; Desai et al, 2018; Kaser et al, 2001; Shirai et al, 2019). Given the high rates of thromboinflammmation in the novel coronavirus 2019 (COVID-19), as well as the well-documented aberrant MK activity in affected patients, TPO silencing offers a potential therapeutic modality in the treatment of COVID-19 and other pathologies associated with thromboinflammation. The current review explores the current clinical applications of TPO silencing and offers insight into a potential role in the treatment of COVID-19.
Keywords: COVID-19; Coronavirus 2019; Megakaryocytes; Thromboinflammation; Thrombopoietin; Thrombopoietin silencing.
. 2021 Jul 3;146:155634.
doi: 10.1016/j.cyto.2021.155634. Online ahead of print.
Clinical applications of thrombopoietin silencing: A possible therapeutic role in COVID-19?
Vincent J Alentado[SUP] 1 [/SUP], Alison R Moliterno[SUP] 2 [/SUP], Edward F Srour[SUP] 3 [/SUP], Melissa A Kacena[SUP] 4 [/SUP]
Affiliations
- PMID: 34247039
- DOI: 10.1016/j.cyto.2021.155634
Abstract
Thrombopoietin (TPO) is most recognized for its function as the primary regulator of megakaryocyte (MK) expansion and differentiation. MKs, in turn, are best known for their role in platelet production. Research indicates that MKs and platelets play an extensive role in the pathologic thrombosis at sites of high inflammation. TPO, therefore, is a key mediator of thromboinflammation. Silencing of TPO has been shown to decrease platelets levels and rates of pathologic thrombosis in patients with various inflammatory disorders (Barrett et al, 2020; Bunting et al, 1997; Desai et al, 2018; Kaser et al, 2001; Shirai et al, 2019). Given the high rates of thromboinflammmation in the novel coronavirus 2019 (COVID-19), as well as the well-documented aberrant MK activity in affected patients, TPO silencing offers a potential therapeutic modality in the treatment of COVID-19 and other pathologies associated with thromboinflammation. The current review explores the current clinical applications of TPO silencing and offers insight into a potential role in the treatment of COVID-19.
Keywords: COVID-19; Coronavirus 2019; Megakaryocytes; Thromboinflammation; Thrombopoietin; Thrombopoietin silencing.